$CDXS
CODEXIS, INC.

2014 Q4 Form 10-Q Financial Statement

#000120037514000051 Filed on November 06, 2014

View on sec.gov

Income Statement

Concept 2014 Q4 2014 Q3 2013 Q4
Revenue $14.19M $7.472M $9.525M
YoY Change 48.98% 89.5% 20.39%
Cost Of Revenue $3.550M $1.532M $4.764M
YoY Change -25.48% 210.12% -17.56%
Gross Profit $10.64M $5.940M $4.761M
YoY Change 123.48% 72.22% 123.21%
Gross Profit Margin 74.98% 79.5% 49.98%
Selling, General & Admin $5.150M $5.157M $5.783M
YoY Change -10.95% -11.57% -20.63%
% of Gross Profit 48.4% 86.82% 121.47%
Research & Development $5.050M $5.038M $8.829M
YoY Change -42.8% -26.25% -16.66%
% of Gross Profit 47.46% 84.81% 185.44%
Depreciation & Amortization $1.470M $1.440M $2.470M
YoY Change -40.49% -44.83% -15.7%
% of Gross Profit 13.82% 24.24% 51.88%
Operating Expenses $10.19M $11.73M $19.38M
YoY Change -47.41% -10.87% -18.1%
Operating Profit $450.0K -$4.255M -$14.62M
YoY Change -103.08% -53.82% -32.11%
Interest Expense $0.00 $0.00 $10.00K
YoY Change -100.0% -100.0% -75.0%
% of Operating Profit 0.0%
Other Income/Expense, Net -$50.00K $57.00K -$20.00K
YoY Change 150.0% 159.09% 100.0%
Pretax Income $400.0K -$4.309M -$9.858M
YoY Change -104.06% -53.3% -37.25%
Income Tax $60.00K $253.0K -$50.00K
% Of Pretax Income 15.0%
Net Earnings $350.0K -$4.562M -$9.813M
YoY Change -103.57% -50.74% -36.85%
Net Earnings / Revenue 2.47% -61.05% -103.02%
Basic Earnings Per Share -$0.12
Diluted Earnings Per Share $9.056K -$0.12 -$252.1K
COMMON SHARES
Basic Shares Outstanding 39.55M shares 38.45M shares 38.11M shares
Diluted Shares Outstanding 38.45M shares

Balance Sheet

Concept 2014 Q4 2014 Q3 2013 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $26.49M $21.52M $25.14M
YoY Change 5.38% -28.07% -44.79%
Cash & Equivalents $26.49M $21.52M $22.13M
Short-Term Investments $0.00 $0.00 $3.005M
Other Short-Term Assets $1.300M $1.700M $3.800M
YoY Change -65.79% -10.53% -29.63%
Inventory $1.395M $1.943M $1.487M
Prepaid Expenses
Receivables $3.870M $3.088M $5.413M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $33.01M $28.21M $35.78M
YoY Change -7.75% -23.03% -40.13%
LONG-TERM ASSETS
Property, Plant & Equipment $3.995M $4.374M $8.446M
YoY Change -52.7% -68.33% -49.27%
Goodwill $3.241M $3.241M $3.241M
YoY Change 0.0% 0.0% 0.0%
Intangibles $6.186M $7.029M $9.560M
YoY Change -35.29% -32.43% -26.09%
Long-Term Investments $700.0K $1.000M $800.0K
YoY Change -12.5% -9.09% -77.78%
Other Assets $294.0K $201.0K $306.0K
YoY Change -3.92% -44.32% -86.32%
Total Long-Term Assets $15.12M $16.59M $23.06M
YoY Change -34.45% -44.32% -42.63%
TOTAL ASSETS
Total Short-Term Assets $33.01M $28.21M $35.78M
Total Long-Term Assets $15.12M $16.59M $23.06M
Total Assets $48.12M $44.79M $58.84M
YoY Change -18.22% -32.58% -41.14%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.673M $2.542M $3.961M
YoY Change 17.98% 70.6% 8.4%
Accrued Expenses $2.619M $2.050M $1.612M
YoY Change 62.47% -4.21% -76.8%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $13.74M $11.00M $11.20M
YoY Change 22.64% 19.38% -31.22%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.528M $4.213M $5.044M
YoY Change -49.88% -18.72% 27.92%
Total Long-Term Liabilities $2.528M $4.213M $5.044M
YoY Change -49.88% -18.72% 27.92%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.74M $11.00M $11.20M
Total Long-Term Liabilities $2.528M $4.213M $5.044M
Total Liabilities $16.26M $19.59M $17.36M
YoY Change -6.3% 36.0% -14.18%
SHAREHOLDERS EQUITY
Retained Earnings -$275.9M -$276.3M -$256.9M
YoY Change 7.42% 11.83% 19.16%
Common Stock $4.000K $4.000K $4.000K
YoY Change 0.0% 0.0% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.31M $25.21M $41.48M
YoY Change
Total Liabilities & Shareholders Equity $48.12M $44.79M $58.84M
YoY Change -18.22% -32.58% -41.14%

Cashflow Statement

Concept 2014 Q4 2014 Q3 2013 Q4
OPERATING ACTIVITIES
Net Income $350.0K -$4.562M -$9.813M
YoY Change -103.57% -50.74% -36.85%
Depreciation, Depletion And Amortization $1.470M $1.440M $2.470M
YoY Change -40.49% -44.83% -15.7%
Cash From Operating Activities $4.970M $1.690M -$3.910M
YoY Change -227.11% -119.81% -17.34%
INVESTING ACTIVITIES
Capital Expenditures -$30.00K -$160.0K -$730.0K
YoY Change -95.89% -184.21% 143.33%
Acquisitions
YoY Change
Other Investing Activities $0.00 $260.0K $290.0K
YoY Change -100.0% -90.88% -97.39%
Cash From Investing Activities -$30.00K $100.0K -$440.0K
YoY Change -93.18% -96.71% -104.07%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 30.00K -360.0K -440.0K
YoY Change -106.82% -3700.0% -218.92%
NET CHANGE
Cash From Operating Activities 4.970M 1.690M -3.910M
Cash From Investing Activities -30.00K 100.0K -440.0K
Cash From Financing Activities 30.00K -360.0K -440.0K
Net Change In Cash 4.970M 1.430M -4.790M
YoY Change -203.76% -126.09% -174.38%
FREE CASH FLOW
Cash From Operating Activities $4.970M $1.690M -$3.910M
Capital Expenditures -$30.00K -$160.0K -$730.0K
Free Cash Flow $5.000M $1.850M -$3.180M
YoY Change -257.23% -121.22% -28.22%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
298370000 USD
CY2013Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
460000 USD
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
513000 USD
CY2013Q3 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
328000 USD
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3961000 USD
CY2014Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2542000 USD
CY2014Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3088000 USD
CY2013Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
5413000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
63000 USD
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-2000 USD
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1612000 USD
CY2014Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2050000 USD
CY2014Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30880000 USD
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
29461000 USD
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-32000 USD
CY2014Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
113000 USD
CY2014Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
301365000 USD
CY2014Q3 us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
53000 USD
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
328000 USD
us-gaap Allowance For Doubtful Accounts Receivable Period Increase Decrease
AllowanceForDoubtfulAccountsReceivablePeriodIncreaseDecrease
53000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2531000 USD
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
2531000 USD
CY2013Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6545000 shares
CY2014Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6473000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6545000 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
6473000 shares
CY2013Q4 us-gaap Asset Impairment Charges
AssetImpairmentCharges
1571000 USD
CY2014Q3 us-gaap Asset Retirement Obligation
AssetRetirementObligation
100000 USD
CY2014Q3 us-gaap Assets
Assets
44792000 USD
CY2013Q4 us-gaap Assets
Assets
58840000 USD
CY2014Q3 us-gaap Assets Current
AssetsCurrent
28205000 USD
CY2013Q4 us-gaap Assets Current
AssetsCurrent
35781000 USD
us-gaap Cost Of Goods Sold
CostOfGoodsSold
9790000 USD
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
886000 USD
us-gaap Assets Fair Value Adjustment
AssetsFairValueAdjustment
0 USD
CY2014Q2 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
292000 USD
CY2014Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
0 USD
CY2014Q1 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
1394000 USD
CY2013Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation
AssetsOfDisposalGroupIncludingDiscontinuedOperation
2179000 USD
CY2013Q4 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
2179000 USD
CY2014Q3 us-gaap Assets Of Disposal Group Including Discontinued Operation Current
AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
0 USD
CY2014Q3 us-gaap Available For Sale Securities
AvailableForSaleSecurities
15631000 USD
CY2013Q4 us-gaap Available For Sale Securities
AvailableForSaleSecurities
19889000 USD
CY2014Q3 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
15163000 USD
CY2013Q4 us-gaap Available For Sale Securities Amortized Cost
AvailableForSaleSecuritiesAmortizedCost
19654000 USD
CY2014Q3 us-gaap Cash
Cash
6900000 USD
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22130000 USD
CY2014Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
21522000 USD
CY2013Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26911000 USD
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
32003000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-5092000 USD
us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-608000 USD
CY2014Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2014Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
39510000 shares
CY2014Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
39510000 shares
CY2014Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
38351000 shares
CY2013Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
494000 USD
CY2014Q3 us-gaap Cost Of Goods Sold
CostOfGoodsSold
1532000 USD
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
38351000 shares
CY2014Q3 us-gaap Common Stock Value
CommonStockValue
4000 USD
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
4000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-31214000 USD
CY2014Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4823000 USD
CY2013Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9230000 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-19271000 USD
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our financial instruments that are potentially subject to concentration of credit risk primarily consist of: cash equivalents, short-term investments, accounts receivable, marketable securities, and restricted cash. We invest cash that is not required for immediate operating needs principally in money market funds and corporate securities through banks and other financial institutions in the United States, as well as in foreign countries.</font></div></div>
us-gaap Cost Of Goods Sold
CostOfGoodsSold
6179000 USD
CY2014Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
4036000 USD
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2001000 USD
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1114000 USD
CY2014Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
4368000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2679000 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
5307000 USD
CY2014Q2 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
188000 USD
CY2014Q3 us-gaap Disposal Group Not Discontinued Operation Loss Gain On Write Down
DisposalGroupNotDiscontinuedOperationLossGainOnWriteDown
188000 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.51
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.83
CY2014Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.12
us-gaap Investment Income Interest
InvestmentIncomeInterest
53000 USD
CY2013Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.24
CY2014Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2376000 USD
CY2013Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3625000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
843000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
2812000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3374000 USD
CY2014Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
7029000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-62000 USD
us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
115000 USD
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
0 USD
us-gaap Gain Or Loss On Sale Of Stock In Subsidiary
GainOrLossOnSaleOfStockInSubsidiary
760000 USD
CY2014Q3 us-gaap Goodwill
Goodwill
3241000 USD
CY2013Q4 us-gaap Goodwill
Goodwill
3241000 USD
CY2013Q3 us-gaap Goodwill
Goodwill
3241000 USD
CY2013 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0 USD
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 USD
us-gaap Goodwill Period Increase Decrease
GoodwillPeriodIncreaseDecrease
0 USD
CY2014Q2 us-gaap Impairment Charge On Reclassified Assets
ImpairmentChargeOnReclassifiedAssets
568000 USD
CY2014Q3 us-gaap Impairment Charge On Reclassified Assets
ImpairmentChargeOnReclassifiedAssets
130000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1841000 USD
us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2013 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0 USD
CY2014Q3 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
1841000 USD
CY2014Q3 us-gaap Incentive From Lessor
IncentiveFromLessor
1800000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-19730000 USD
us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-31530000 USD
CY2013Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-9227000 USD
CY2014Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-4309000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-41000 USD
CY2013Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
35000 USD
CY2014Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
253000 USD
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-314000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-2164000 USD
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1418000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2316000 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-833000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
5288000 USD
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1923000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-155000 USD
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1100000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
456000 USD
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
614000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
1080000 USD
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
194000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
74000 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
37000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-4000 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
734000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-600000 USD
us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
0 USD
CY2014Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
7029000 USD
CY2013Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
9560000 USD
CY2013Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
693000 USD
CY2014Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
1351000 USD
CY2014Q3 us-gaap Inventory Net
InventoryNet
1943000 USD
CY2013Q4 us-gaap Inventory Net
InventoryNet
1487000 USD
CY2014Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
575000 USD
CY2013Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
763000 USD
CY2014Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
17000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-89000 USD
CY2013Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
31000 USD
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
58840000 USD
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
11199000 USD
CY2014Q3 us-gaap Liabilities Current
LiabilitiesCurrent
11004000 USD
CY2014Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
3000 USD
CY2013Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
9000 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
15000 USD
CY2014Q1 us-gaap Lessee Leasing Arrangements Operating Leases Renewal Term
LesseeLeasingArrangementsOperatingLeasesRenewalTerm
P1Y
CY2014Q1 us-gaap Lessee Leasing Arrangements Operating Leases Term Of Contract
LesseeLeasingArrangementsOperatingLeasesTermOfContract
P3Y
CY2013Q4 us-gaap Liabilities
Liabilities
17357000 USD
CY2014Q3 us-gaap Liabilities
Liabilities
19585000 USD
CY2014Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44792000 USD
CY2014Q3 us-gaap Loss Contingency Estimate Of Possible Loss
LossContingencyEstimateOfPossibleLoss
600000 USD
CY2013Q4 us-gaap Marketable Securities
MarketableSecurities
3005000 USD
CY2014Q3 us-gaap Marketable Securities
MarketableSecurities
0 USD
CY2014Q3 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
1031000 USD
CY2013Q4 us-gaap Marketable Securities Noncurrent
MarketableSecuritiesNoncurrent
795000 USD
CY2014Q3 us-gaap Money Market Funds At Carrying Value
MoneyMarketFundsAtCarryingValue
14600000 USD
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-bottom:10px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Business</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In these notes to the condensed consolidated financial statements, the &#8220;Company,&#8221; "we," "us,'" and "our" refers to Codexis, Inc. and its subsidiaries on a consolidated basis.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Codexis, Inc. was incorporated in the State of Delaware in January 2002. We develop biocatalysts for the pharmaceutical and fine chemicals markets. Our proven technologies enable scale-up and implementation of biocatalytic solutions to meet customer needs for rapid, cost-effective and sustainable process development, from research to manufacturing. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Biocatalysts are enzymes or microbes that initiate and/or accelerate chemical reactions. Manufacturers have historically used naturally occurring biocatalysts to produce many goods used in everyday life. However, inherent limitations in naturally occurring biocatalysts have restricted their commercial use. Our proprietary technology platform is able to overcome many of these limitations, allowing us to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. </font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have commercialized our technology and products in the pharmaceuticals market, which is our primary business focus. Our pharmaceutical customers, which include several of the largest global pharmaceutical companies, use our technology, products and services in their manufacturing processes and process development, including in the production of some of the world's best-selling and fastest growing drugs.</font></div><div style="line-height:120%;padding-top:12px;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have recently begun to use our technology to develop biocatalysts for use in the fine chemicals market. The fine chemicals market is similar to our pharmaceutical business and consists of several large market verticals, including: food, animal feed, polymers, flavors, fragrances, and agricultural chemicals.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We create our products by applying our CodeEvolver</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> directed evolution technology platform, which introduces genetic mutations into microorganisms, giving rise to changes in the enzymes that they produce. Once we identify potentially beneficial mutations, we test combinations of these mutations until we have created variant enzymes that exhibit marketable performance characteristics superior to competitive products. This process allows us to make continuous, efficient improvements to the performance of our enzymes. We are also pursuing opportunities to provide licenses to certain pharmaceutical customers to use our CodeEvolver</font><font style="font-family:inherit;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></font><font style="font-family:inherit;font-size:10pt;"> platform for their internal development purposes.</font></div></div>
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-635000 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
288000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
4680000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
13713000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-19093000 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4653000 USD
us-gaap Net Income Loss
NetIncomeLoss
-31489000 USD
CY2014Q3 us-gaap Net Income Loss
NetIncomeLoss
-4562000 USD
us-gaap Net Income Loss
NetIncomeLoss
-19416000 USD
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-9262000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-31295000 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-19562000 USD
CY2013Q4 us-gaap Noncurrent Assets
NoncurrentAssets
18312000 USD
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 operating_segment
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 reporting_unit
us-gaap Operating Expenses
OperatingExpenses
40678000 USD
CY2014Q3 us-gaap Operating Expenses
OperatingExpenses
11727000 USD
us-gaap Operating Expenses
OperatingExpenses
53692000 USD
CY2013Q3 us-gaap Operating Expenses
OperatingExpenses
13157000 USD
CY2014Q3 us-gaap Noncurrent Assets
NoncurrentAssets
11403000 USD
CY2014Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4255000 USD
CY2013Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-9214000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
14706000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
2736000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
2677000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
2827000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
2743000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
3054000 USD
CY2014Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
669000 USD
us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
200000 USD
CY2014Q3 us-gaap Operating Leases Income Statement Sublease Revenue
OperatingLeasesIncomeStatementSubleaseRevenue
100000 USD
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
306000 USD
CY2014Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
201000 USD
CY2013Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
32000 USD
CY2014Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-261000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
275000 USD
us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
145000 USD
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-172000 USD
CY2014Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
160000 USD
CY2013Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-17000 USD
us-gaap Other Expenses
OtherExpenses
288000 USD
CY2014Q3 us-gaap Other Expenses
OtherExpenses
57000 USD
us-gaap Other Expenses
OtherExpenses
183000 USD
CY2013Q3 us-gaap Other Expenses
OtherExpenses
22000 USD
CY2014Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4213000 USD
CY2013Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
5044000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
815000 USD
us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
0 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
267000 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
447000 USD
CY2014Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2014Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2014Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2014Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2014Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2013Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1567000 USD
CY2014Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1652000 USD
CY2014Q1 us-gaap Proceeds From Divestiture Of Interest In Consolidated Subsidiaries
ProceedsFromDivestitureOfInterestInConsolidatedSubsidiaries
1500000 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1500000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
3000000 USD
us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
13410000 USD
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
0 USD
us-gaap Proceeds From Sale Of Property Held For Sale
ProceedsFromSaleOfPropertyHeldForSale
281000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
150000 USD
us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
166000 USD
CY2014Q1 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
760000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
180000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
288000 USD
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37866000 USD
CY2014Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
37070000 USD
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8446000 USD
CY2014Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4374000 USD
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
53000 USD
us-gaap Provision For Loan Lease And Other Losses
ProvisionForLoanLeaseAndOtherLosses
328000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
4936000 USD
us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
7176000 USD
CY2014Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
3364000 USD
CY2013Q3 us-gaap Research And Development Arrangement Contract To Perform For Others Compensation Earned
ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned
2028000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
22776000 USD
CY2013Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6831000 USD
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17708000 USD
CY2014Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
5038000 USD
CY2014Q3 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
711000 USD
CY2013Q4 us-gaap Restricted Cash And Investments Noncurrent
RestrictedCashAndInvestmentsNoncurrent
711000 USD
us-gaap Revenues
Revenues
22397000 USD
CY2013Q3 us-gaap Revenues
Revenues
3943000 USD
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-256859000 USD
CY2014Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-276275000 USD
us-gaap Revenues
Revenues
21116000 USD
CY2014Q3 us-gaap Revenues
Revenues
7472000 USD
CY2013Q3 us-gaap Royalty Revenue
RoyaltyRevenue
839000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
5617000 USD
us-gaap Royalty Revenue
RoyaltyRevenue
2300000 USD
CY2014Q3 us-gaap Royalty Revenue
RoyaltyRevenue
1546000 USD
CY2014Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
2562000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
15161000 USD
us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
8323000 USD
CY2013Q3 us-gaap Sales Revenue Goods Gross
SalesRevenueGoodsGross
1076000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
16791000 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
21126000 USD
CY2013Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5832000 USD
CY2014Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
5157000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3630000 USD
us-gaap Share Based Compensation
ShareBasedCompensation
3361000 USD
CY2014Q3 us-gaap Share Based Compensation
ShareBasedCompensation
1055000 USD
CY2013Q3 us-gaap Share Based Compensation
ShareBasedCompensation
626000 USD
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.34
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
41483000 USD
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
136796 shares
CY2014Q3 us-gaap Stockholders Equity
StockholdersEquity
25207000 USD
CY2014Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
-261000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
275000 USD
CY2013Q3 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
32000 USD
us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
145000 USD
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent liabilities at the date of the condensed consolidated financial statements, and the reported amounts of revenue and expenses during the reporting period. We regularly assess these estimates which primarily affect revenue recognition, accounts receivable, inventories, the valuation of investment securities and marketable securities, assets held for sale, intangible assets, goodwill arising out of business acquisitions, accrued liabilities, stock awards and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the condensed consolidated financial statements.</font></div></div>
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38002000 shares
CY2014Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38450000 shares
CY2013Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38102000 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38063000 shares
CY2014Q3 cdxs Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax
468000 USD
CY2013Q4 cdxs Availableforsale Securities Accumulated Gross Unrealized Gainbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedGainbeforeTax
235000 USD
CY2014Q3 cdxs Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax
0 USD
CY2013Q4 cdxs Availableforsale Securities Accumulated Gross Unrealized Lossbefore Tax
AvailableforsaleSecuritiesAccumulatedGrossUnrealizedLossbeforeTax
0 USD
CY2014Q2 cdxs Disposal Group Including Discontinued Operation Long Lived Assets Reclassified
DisposalGroupIncludingDiscontinuedOperationLongLivedAssetsReclassified
333000 USD
CY2014Q3 cdxs Disposal Group Including Discontinued Operation Long Lived Assets Reclassified
DisposalGroupIncludingDiscontinuedOperationLongLivedAssetsReclassified
333000 USD
CY2014Q1 cdxs Lessee Leasing Arrangements Operating Leases Numberof Renewals
LesseeLeasingArrangementsOperatingLeasesNumberofRenewals
2 extension
cdxs Maturity Date Of Highly Liquid Investments
MaturityDateOfHighlyLiquidInvestments
P3M
CY2014Q3 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
6190000 USD
CY2013Q4 cdxs Property Plantand Equipment Net Excluding Constructionin Progress
PropertyPlantandEquipmentNetExcludingConstructioninProgress
8405000 USD
CY2014Q3 cdxs Property Plantand Equipment Net Excluding Impairmentof Long Lived Assets Heldforsale
PropertyPlantandEquipmentNetExcludingImpairmentofLongLivedAssetsHeldforsale
6215000 USD
CY2013Q4 cdxs Property Plantand Equipment Net Excluding Impairmentof Long Lived Assets Heldforsale
PropertyPlantandEquipmentNetExcludingImpairmentofLongLivedAssetsHeldforsale
8446000 USD
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2014
dei Document Period End Date
DocumentPeriodEndDate
2014-09-30
dei Document Type
DocumentType
10-Q
dei Entity Central Index Key
EntityCentralIndexKey
0001200375
CY2014Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
39549301 shares
dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
CODEXIS INC

Files In Submission

Name View Source Status
0001200375-14-000051-index-headers.html Edgar Link pending
0001200375-14-000051-index.html Edgar Link pending
0001200375-14-000051.txt Edgar Link pending
0001200375-14-000051-xbrl.zip Edgar Link pending
cdxs-20140930.xml Edgar Link completed
cdxs-20140930.xsd Edgar Link pending
cdxs-20140930_cal.xml Edgar Link unprocessable
cdxs-20140930_def.xml Edgar Link unprocessable
cdxs-20140930_lab.xml Edgar Link unprocessable
cdxs-20140930_pre.xml Edgar Link unprocessable
cdxs_20140930x10q.htm Edgar Link pending
cdxs_20140930xex311.htm Edgar Link pending
cdxs_20140930xex312.htm Edgar Link pending
cdxs_20140930xex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
gordonsangster71014offerle.htm Edgar Link pending
gordonsangster71014of_image1.gif Edgar Link pending
gskcollaborationandlicense.htm Edgar Link pending
logoa01.jpg Edgar Link pending
o_tooleseparationagreement.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending